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Summary 
Background and Purpose: Calcitonin gene-related peptide (CGRP) is a potent 
vasodilator, implicated in the pathogenesis of migraine. CGRP activates a receptor 
complex comprising, calcitonin receptor-like receptor (CLR) and receptor activity-
modifying protein 1 (RAMP1). In vitro studies indicate recycling of CLR•RAMP1 is 
regulated by degradation of CGRP in early endosomes by endothelin-converting 
enzyme-1 (ECE-1). However, it is not known if ECE-1 regulates the resensitization of 
CGRP-induced responses in functional arterial tissue. 
Experimental Approach: CLR, ECE-1a-d and RAMP1 expression in rat mesenteric 
artery smooth muscle cells (RMA-SMCs) and mesenteric arteries was analyzed by 
RT-PCR and by immunofluorescence and confocal microscopy. CGRP-induced 
signaling in cells was examined by measuring cAMP production and ERK activation. 
CGRP-induced relaxation of arteries was measured by isometric wire myography. 
ECE-1 was inhibited using the specific inhibitor, SM-19712. 
Key Results: RMA-SMCs and arteries contained mRNA for CLR, ECE-1a-d and 
RAMP1. ECE-1 was present in early endosomes of RMA-SMCs and in the smooth 
muscle layer of arteries. CGRP induced endothelium-independent relaxation of 
arteries. ECE-1 inhibition had no effect on initial CGRP-induced responses but 
reduced cAMP generation in RMA-SMCs and vasodilation in mesenteric arteries 
responses to subsequent CGRP challenges. 
Conclusions and Implications: ECE-1 regulates the resensitization of responses to 
CGRP in RMA-SMCs and mesenteric arteries. CGRP-induced relaxation does not A
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involve endothelium-derived pathways. This is the first report of ECE-1 regulating 
CGRP responses in SMCs and arteries. ECE-1 inhibitors may attenuate an important 
vasodilatory pathway, implicated in primary headaches and may represent a new 
therapeutic approach for the treatment of migraine. 
 
Keywords: calcitonin gene-related peptide, calcitonin receptor-like receptor, receptor 
activity-modifying protein, endothelin-converting enzyme-1, endosome, mesenteric, 
migraine, smooth muscle cell, vasodilation. 
Abbreviations 
CGRP, calcitonin gene-related peptide; CLR, calcitonin receptor-like receptor; ECE-
1, endothelin-converting enzyme-1; EEA1, early endosomal antigen 1; ERK, 
extracellular-regulated protein kinase; GPCR, G protein-coupled receptor; RAMP, 
receptor activity-modifying protein; RMA-SMC, rat mesenteric artery smooth muscle 
cell. 
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Introduction 
CGRP belongs to the calcitonin family of peptides, which also includes 
adrenomedullin, calcitonin, intermedin (adrenomedullin 2) and amylin. CGRP is 
widely distributed in sensory nerves throughout the central and peripheral nervous 
system (Brain et al., 2004). CGRP is a potent vasodilator, increases blood flow and 
promotes mast cell degranulation, angiogenesis and endothelial cell proliferation 
(Brain et al., 1985; Haegerstrand et al., 1990; Ohno et al., 2008; Reynier-Rebuffel et 
al., 1994). In contrast, CGRP has anti-proliferative effects in SMCs (Chattergoon et 
al., 2005; Li et al., 1997).  The relaxing effects of CGRP on the vasculature can be 
mediated by activating either endothelial cells or smooth muscle cells. For example, 
CGRP relaxes human radial, coronary, gastric and cerebral arteries via an 
endothelium-dependent pathway (Thom et al., 1987). Whereas CGRP acts solely on 
smooth muscle cells receptors in human and porcine coronary arteries (Shoji et al., 
1987). In addition to vasodilatation CGRP has been shown to be beneficial in 
protecting against myocardial ischaemia (Wu et al., 2001) and heart and kidney 
damage caused by hypertension (Supowit et al., 2005). 
Noxious stimuli and trauma can lead to release of CGRP and another neuropeptide, 
substance P from primary sensory neurons. Centrally, release of CGRP and substance 
P facilitates nociceptive transmission and in the periphery they mediate neurogenic 
inflammation, which is characterized by neutrophil infiltration, oedema and 
vasodilatation (McDonald, 1988). These processes are important characteristics of 
many human diseases including asthma, arthritis, and inflammatory bowel diseases. 
CGRP has been implicated in the pathogenesis of migraine as infusion of CGRP 
caused delayed headaches in patients suffering from primary headache diseases A
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(Lassen et al., 2002) and increased levels of CGRP have been detected in the serum 
and saliva of patients during migraine attacks (Bellamy et al., 2006; Cady et al., 2009; 
Goadsby et al., 1990). Current migraine treatments, include triptans (serotonin 5-
HT1B and 5-HT1D receptor agonists) which constrict intra-cranial blood vessels and 
reduce release of neuropeptides such as CGRP. However, this treatment is not 
effective in all migraine patients. Therefore, other drug targets are needed for the 
treatment of migraine. There are now a number of non-peptidic CGRP receptor 
antagonists, which are showing promise for the treatment of migraine in clinical trials. 
The first described non-peptidic antagonist was olcegepant (formerly BIBN4096BS) 
(Doods et al., 2000), followed by telcagepant (formerly MK-0974) (Paone et al., 
2007). Both olcegepant and telcagepant have both been shown to have clinical 
efficacy in the acute treatment of migraine (Connor et al., 2011; Connor et al., 2009; 
Ho et al., 2008a; Ho et al., 2008b; Olesen et al., 2004), but trials have now been 
discontinued.  
The receptor for CGRP is an unusual heterodimeric receptor complex comprising the 
G protein-coupled receptor (GPCR), CLR and a single transmembrane protein, 
RAMP1 (McLatchie et al., 1998). A third protein called CGRP-receptor component 
protein is required for efficient CGRP-induced signaling (Evans et al., 2000). There 
are three RAMP family members, which can all heterodimerize with CLR (McLatchie 
et al., 1998). CLR•RAMP2 and CLR•RAMP3 are normally referred to as high 
affinity adrenomedullin receptors. However, high concentrations of CGRP and 
intermedin can also activate these receptors (Hong et al., 2012). CLR•RAMP1 
undergoes agonist-dependent internalization, a process that requires interaction with 
β-arrestins (Hilairet et al., 2001). CLR•RAMP1 and CGRP traffic together to early 
endosomes, but the duration of the stimulus determines the post-endocytic sorting of A
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CLR•RAMP1 (Cottrell et al., 2007; Cottrell et al., 2005). The recycling of 
CLR•RAMP1 is regulated by the metallopeptidase ECE-1, which degrades CGRP, 
promoting the release of β-arrestins to allow CLR•RAMP1 to recycle to the cell-
surface, mediating resensitization (Padilla et al., 2007). 
In the current study, we examined the role of ECE-1 in regulating CLR•RAMP1 
resensitization in RMA-SMCs and in controlling resensitization of the vasodilatory 
effects of CGRP in intact mesenteric arteries. Our aims were to; 1) determine whether 
ECE-1 and CLR•RAMP1 are coexpressed in vascular SMCs of resistance-sized 
arteries; 2) investigate whether ECE-1 controls resensitization of CGRP-signaling in 
vascular SMCs; and 3) determine if ECE-1 controls resensitization of the vasodilatory 
effects of CGRP. Our results show that ECE-1 is expressed in arteries important for 
the regulation of blood pressure and its activity promotes resensitization of CGRP-
induced cAMP generation in RMA-SMCs and vasodilation in rat mesenteric 
resistance arteries. 
 
 
 
Methods 
Reagents 
Sources of antibodies and reagents: rabbit anti-rat CLR (RK11) and anti-rat RAMP1 
(9891) were a gift from Nigel W. Bunnett (Monash University, Victoria, Australia; 
Cottrell et al., 2005); goat anti-human ECE-1 (R&D Systems, Abingdon, UK); mouse 
anti-early endosomal antigen-1 (EEA1, BD Transduction Laboratories, Oxford, UK); 
α-smooth muscle actin (smooth muscle cell marker; A5228; Sigma-Aldrich Company 
Ltd, Dorset, UK); mouse anti-rat platelet endothelial cell adhesion molecule-1 A
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(endothelial cell marker; PECAM-1/CD31, TLD-3A12, Millipore, Watford, UK); 
mouse anti-pERK1/2 (E-4) and rabbit anti-ERK2 (C-14) (Insight Biotechnology Ltd, 
Wembley, UK); donkey anti-mouse, goat or rabbit IgG coupled to fluorescein 
isothiocyanate, Rhodamine Red-X or Cy5 (Stratech Scientific Limited, Newmarket, 
UK); rat α-CGRP (Bachem, Weil am Rhein, Germany), apamin (Latoxan, Valence, 
France); SM-19712 (4-Chloro-N-[[(4-cyano-3-methyl-1-phenyl-1H-pyrazol-5-
yl)amino]carbonyl] benzenesulphonamide sodium salt, acetylcholine, L-NAME (NG-
nitro-L-arginine methyl ester), TRAM-34 (1-[(2-Chlorophenyl)diphenylmethyl]-1H-
pyrazole), indomethacin and IBMX (3-isobutyl-1-methylxanthine) (Sigma-Aldrich 
company Ltd.). Other reagents were from Sigma-Aldrich Company Ltd. 
Animals 
Male Wistar rats (200–300 g) were killed by cervical dislocation following 
institutional guidelines for animal welfare and schedule 1 of the Animals (scientific 
procedures) Act 1986. The mesenteric vascular bed was excised and immediately 
placed in ice cold Krebs solution containing (mM): NaCl, 118.0; NaCO3, 24; KCl, 
3.6; KH2PO4, 1.2; MgSO4⋅7H2O, 1.2; glucose, 11.0; CaCl2, 2.5. 
Primary Cell Culture 
RMA-SMCs were obtained using an explant method. Briefly, the mesenteric vascular 
tree was pinned out and mesenteric arteries (3rd order) were cut longitudinally and 
pieces (1 mm) placed in DMEM containing 10% heat-inactivated foetal bovine 
serum, 1% non-essential amino acids, penicillin-streptomycin and fungizone. After 7-
10 days, migrated cells were pooled and maintained in medium (as above). Cells were 
used for experiments between passages 2-4. All cells were routinely grown in 95% 
air, 5% CO2 at 37°C. 
Immunofluorescence  A
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RMA-SMCs were washed in 100 mM PBS, pH 7.4, and fixed in PBS containing 4% 
paraformaldehyde, pH 7.4 (20 min, 4°C) or in methanol (100%, -20ºC, 10 min). Cells 
were washed with PBS containing 0.1% saponin and 2% normal horse serum (30 min, 
room temperature). Proteins were localized using the primary antibodies: ECE-1 
(1:200), α-smooth muscle actin (1:200) and EEA1 (1:500) (overnight, 4°C). Cells 
were washed, incubated with appropriate secondary antibodies (1:500, 2 h, room 
temperature) and mounted in Vectashield (Vector Laboratories Ltd., Peterborough, 
UK). 
To obtain whole mount preparations, arteries were prepared using a perfusion fix 
protocol; the mesenteric vascular bed was excised and perfused with Krebs solution 
for 5 min as previously described (McNeish et al., 2002). Arteries were then 
perfusion fixed for 10 min with 100 mM PBS, pH 7.4 containing 1% 
paraformaldehyde, 10 µM sodium azide and 10 mM betaine. Arteries (3rd order) were 
excised, cut longitudinally and pinned flat on sylgard plates and fixed (100 mM PBS, 
pH 7.4, 4% paraformaldehyde, 2 h, 4ºC). Artery whole mounts were washed in PBS 
containing 10% normal horse serum and 0.3% Triton-X-100 (1 h, room temperature) 
and proteins localized using the primary antibodies: ECE-1 (1:200) and PECAM-1 
(1:200)  (48 h, 4ºC). Whole mounts were washed (1 h, room temperature), incubated 
with appropriate secondary antibodies (1:500, 2 h, room temperature) and mounted in 
ProLong® Gold (Invitrogen, Paisley, UK). To obtain sections, rat mesenteric arteries 
(3rd order) were embedded in OCT and sectioned at 10 µm and fixed in 100 mM PBS, 
pH 7.4 containing 4% paraformaldehyde (30 min, 4ºC). Sections were washed in PBS 
containing 10% normal horse serum and 0.3% Triton-X-100 (1 h, room temperature) 
and proteins localized using the primary antibodies: ECE-1 (1:200), CLR (1:2000), 
RAMP1 (1:1000) and α-smooth muscle actin (1:200) (overnight, 4ºC). Sections were A
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washed (1 h, room temperature), incubated with appropriate secondary antibodies 
(1:500, 2 h, room temperature) and mounted in ProLong® Gold (Invitrogen, Paisley, 
UK).  
Confocal Microscopy 
For epifluorescence microscopy, cells were observed using a Leica DMI4000B 
microscope using NPlanL20X/0.35 objective with a Leica DFC420C camera. For 
confocal microscopy, cells, whole mounts and sections were observed with a Zeiss 
laser-scanning confocal microscope (LSM Meta 510) using EC Plan-Neofluar 
20x/0.5, EC Plan-Neofluar 40x/1.3 Oil DIC and Plan-Apochromat 63x/1.4 Oil DIC 
objectives. Images were collected at a zoom of 1-2 and an iris of <3 µm, and at least 
five optical sections were taken at intervals of 0.5 µm. Single sections are shown. 
Images were processed using ImageJ and Adobe Photoshop software. 
Isolated artery tension recording 
Mesenteric arteries (2 mm segments, 3rd order) were mounted in a Mulvany-Halpern 
myograph (model 400A, Danish Myotechnology) in Krebs solution, gassed with 95% 
O2, 5% CO2 and maintained at 37°C. After equilibration for 20 min, vessels were 
normalized to a tension equivalent to that generated at 0.9 times the diameter of the 
vessel at 80 mm Hg. Smooth muscle tension was recorded with an isometric force 
transducer and Powerlab software (ADI, Australia). Vessel viability was assessed by 
significant constriction (>10 mN) to 3 µM phenylephrine (PE) and a relaxation of 
>95% of the PE tone by acetylcholine (1 µM). To measure responses to CGRP, 
mesenteric arteries were first contracted by exposing to an increasing concentration of 
PE until maximal constriction was achieved. A concentration of PE producing 
approximately 70% of this contraction was used in all further studies. Arteries were 
then exposed to increasing concentrations of CGRP (1 pM-3 nM) and repeated in the A
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presence of a combination of L-NAME (100 µM, nitric oxide synthase inhibitor), 
indomethacin (10 µM, nonselective inhibitor of cyclooxygenase-1 and -2), apamin 
(50 nM, selective small conductance Ca2+-activated K+-channel (SKCa) inhibitor) and 
TRAM34 (10 µM, intermediate KCa (IKCa) inhibitor) to assess the role of the 
endothelium in CGRP-induced relaxation. To assess the role of ECE-1 on the 
resensitization of responses to CGRP, PE-constricted arteries were relaxed with 
CGRP (1 pM-3 nM), washed, constricted again and a CGRP challenge repeated after 
5 and 30 min. Following a 1 h rest period, arteries were incubated with SM-19712 (10 
µM, 30 min) and the challenges with CGRP repeated. Time controls were performed 
to ensure that responses to CGRP were maintained in the absence of SM-19712. 
Drug Treatments 
Confluent wells (12-well plates) of RMA-SMCs were used for experimentation. To 
measure CGRP-induced cAMP generation, RMA-SMCs were serum-starved in 
Hank’s balanced salt solution (2 h), incubated with vehicle (control) or SM-19712, 
challenged with vehicle (control) or CGRP (10 nM), washed, incubated in CGRP-free 
medium (30 min) and cAMP generation to a subsequent challenge of CGRP (10 nM) 
recorded. To inhibit phosphodiesterase activity, RMA-SMCs were incubated with 
IBMX (500 µM), 15 min prior to the second challenge with CGRP (10 nM). Controls 
included appropriate vehicle and SM-19712 was present throughout the experimental 
time course. To measure CGRP-induced ERK activation, RMA-SMCs were serum-
starved in DMEM containing 0.1% BSA (16 h), prior to stimulation with CGRP (10 
nM).  
Measurement of cAMP 
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cAMP generation in response to CGRP in RMA-SMCs was measured using a Cyclic 
AMP XP™ Assay Kit according to the manufacturer’s guidelines (New England 
Biolabs, Hitchin, UK). 
SDS-PAGE and Western Blotting 
Cell lysates (10 µg) were prepared as described (Cottrell et al., 2009). Proteins were 
separated by SDS-PAGE (12% acrylamide) and transferred to polyvinylidene fluoride 
membranes. Membranes were incubated with antibodies to pERK1/2 (1:1000) and 
ERK2 (1:10,000) overnight at 4°C. Membranes were treated with secondary 
antibodies coupled to horseradish peroxidase (1:10,000) and immunoreactive proteins 
visualized by enhanced chemiluminescence and quantified using an ImageQuant RT 
ECL machine (GE Healthcare, Little Chalfont, UK) with ImageQuantTL software. 
Reverse Transcription-PCR 
RNA from intact rat mesenteric arteries (3rd order) and RMA-SMCs was isolated 
using Trizol (Invitrogen) and was reverse-transcribed using standard protocols with 
random hexamers and TaqMan reverse transcription reagents (Applied Biosystems, 
Carlsbad, CA, USA). Subsequent PCR reactions used primers specific for rat CLR, 
RAMP1 and ECE-1 isoforms (Supplementary Table 1). Control reactions omitted 
reverse transcriptase. PCR products were separated by electrophoresis, stained with 
ethidium bromide, and sequenced to confirm identity.  
Antibody Preadsorption 
Membranes were prepared from HEK cells transfected with CLR•RAMP1, ECE-1c-
GFP or empty vector (control), were prepared as described (Cottrell et al., 2009). 
CLR (1:2000), RAMP1 (1:1000) and ECE-1 antibody (1:200) were rotated with 
membrane proteins (5 mg ml-1) in PBS containing 10% normal horse serum, 0.3% 
Triton X-100 (overnight, 4°C) before use.  A
cc
ep
te
d 
A
rti
cl
e
© 2012 The Authors 
British Journal of Pharmacology © 2012 The British Pharmacological Society 
12
Statistics and Nomenclature 
Results are expressed as mean±S.E. of n≥3 experiments and were compared using 
one-way ANOVA with Tukey’s post-test or Student's t test, with p<0.05 (*) 
considered to be significant. Sigmoidal concentration response curves were generated 
in Prism (GraphPad, San Diego, USA) using a four-parameter logistic equation fitted 
to the Hill equation (with variable slope). Immunofluorescence images and Western 
blots represent n≥3 experiments. For nomenclature of drugs and molecular targets, the 
British Journal of Pharmacology's Guide to Receptors and Channels was used 
(Alexander et al., 2011). 
 
 
 
Results 
CGRP causes vasodilatation of rat mesenteric arteries via an endothelium-
independent mechanism. CGRP is a potent vasodilatory peptide in rat mesenteric 
resistance arteries (Kawasaki et al., 1988). In order to examine if ECE-1 regulates 
CGRP-induced relaxation of rat mesenteric arteries, we first determined the site of 
action of CGRP. We hypothesized that CGRP would act on SMCs directly and 
relaxation would occur via an endothelium-independent mechanism. In vehicle-
treated arteries, CGRP induced concentration-dependent relaxation (CGRP pEC50, 
10.49±0.07; Supplemental Figure 1). Arteries were then challenged with CGRP in the 
presence of inhibitors of endothelium-derived relaxation pathways. Incubation with L-
NAME (nitric oxide synthase inhibitor) and indomethacin (nonselective inhibitor of 
cyclooxygenase-1 and -2) or a combination of L-NAME, indomethacin, apamin 
(selective small conductance Ca2+-activated K+-channel (SKCa) inhibitor) and A
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TRAM34 (intermediate KCa (IKCa) inhibitor) had no effect on CGRP-induced 
relaxation (CGRP pEC50, 10.46±0.07 and 10.45±0.04, respectively; Supplemental 
Figure 1).  
RMA-SMCs express mRNA for CLR, RAMP1 and ECE-1 isoforms and ECE-1 
is localized to early endosomes in RMA-SMCs.  To assess if ECE-1 is appropriately 
localized to regulate CLR•RAMP1, we first characterized cultured RMA-SMCs. Our 
cultured cells were all positive for the SMC marker, α-smooth muscle actin (Figure 
1A). Next, we examined expression of CLR, RAMP1 and all four ECE-1 isoforms in 
RMA-SMCs by RT-PCR. We amplified mRNA of expected sizes for CLR, RAMP1 
and each of ECE-1 isoforms and confirmed identity by sequencing (Figure 1B). We 
have previously shown that CGRP internalizes with CLR•RAMP1 and is degraded by 
ECE-1 in the early endosomes of HEK-CLR•RAMP1 cells (Cottrell et al., 2005; 
Padilla et al., 2007). To determine if ECE-1 is appropriately localized to perform this 
function in RMA-SMCs we used immunofluorescence and confocal microscopy with 
antibodies to ECE-1 and a marker for early endosomes, EEA1. Immunoreactive ECE-
1 was detected in intracellular vesicles in α-smooth muscle actin-positive cells and 
colocalized with EEA1 (Figure 1C).  Thus, ECE-1 is present in the early endosomes 
of RMA-SMCs where it may degrade CGRP to regulate recycling of CLR•RAMP1. 
RMA-SMCs express a functional CGRP receptor that is regulated by ECE-1. To 
determine whether the CLR and RAMP1 expressed in RMA-SMC form a functional 
CGRP receptor, we examined if CGRP (10 pM-1 µM) induced generation of cAMP. 
CGRP induced a concentration dependent increase in cAMP generation (Figure 2A). 
To further determine the functionality of the CGRP receptor in RMA-SMCs we 
examined CGRP-induced extracellular-regulated protein kinase (ERK) activation. 
RMA-SMCs were challenged with CGRP (10 nM, 0-10 min) and levels of A
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phosphorylated pERK1/2 and total ERK2 determined by Western blotting. CGRP 
induced an increase in levels of phosphorylated ERK1 and ERK2 at both time points 
examined (ERK1, 2±0.4-fold, 2 min, 1.2±0.1-fold, ERK2, 1.9±0.6-fold, 2 min, 
1.3±0.1-fold; 10 min), indicating that RMA-SMCs express a receptor, through which 
CGRP can activate ERK1 and ERK2 (Figure 2B). 
ECE-1 regulates resensitization of CGRP-induced cAMP generation RMA-
SMCs. To determine if ECE-1 regulates resensitization of CGRP responses in RMA-
SMCs, we examined the effect of the specific ECE-1 inhibitor, SM-19712 (Umekawa 
et al., 2000) on resensitization of CGRP-induced cAMP generation. RMA-SMCs 
were incubated with vehicle (control) or SM-19712 and then challenged with vehicle 
or CGRP (10 min) to desensitize CLR•RAMP1. Cells were washed, incubated in 
CGRP-free medium (30 min) to allow resensitization to proceed and then challenged 
with CGRP. cAMP generation to the second challenge of CGRP was then determined 
for each group. In cells vehicle-treated cells, resensitization was 70±12% (compared 
to unstimulated vehicle control [100%], n=4) (Figure 2C). In contrast, in SM-19712-
treated cells, resensitization was strongly inhibited (35±10% compared to 
unstimulated SM-19712 control [100%], n=4) (Figure 2C).  
CLR, RAMP1 and ECE-1 are localized to the smooth muscle layer of rat 
mesenteric arteries.  We examined expression of CLR, RAMP1 and all four ECE-1 
isoforms in intact rat primary mesenteric arteries by RT-PCR. We amplified mRNA 
of expected sizes for CLR, RAMP1 and each of ECE-1 isoforms and confirmed 
identity by sequencing (Figure 3A). Examination of ECE-1 expression at the protein 
level was determined by staining whole mounts of rat mesenteric arteries. 
Immunoreactive ECE-1 was detected in the PECAM-1-positive (endothelial) layer 
and PECAM-1-negative (smooth muscle) layers of arteries (Figure 3B). We also A
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examined expression of CLR, RAMP1 and ECE-1 expression in sections of artery. 
We observed immunoreactive CLR, RAMP1 and ECE-1 in the smooth muscle layer 
(Figure 3C). Preadsorption of the ECE-1, CLR and RAMP1 antibodies with 
membranes from HEK-ECE-1c-GFP cells (ECE-1) or HEK-CLR•RAMP1 (CLR and 
RAMP1) abolished staining compared to membranes from cells expressing empty 
vector (Supplementary Figure 2), confirming the specificity of antibodies for 
detecting CLR, RAMP1 and ECE-1. Thus, ECE-1 is appropriately localized to 
regulate CGRP-induced responses in rat mesenteric arteries. 
ECE-1 regulates the resensitization of CGRP-induced vasodilatation in rat 
mesenteric arteries. To investigate if ECE-1 regulates the resensitization of CGRP-
induced responses in intact tissues, we examined the effect of SM-19712 on CGRP-
induced relaxation of rat mesenteric arteries. Arteries were incubated with vehicle 
(control), challenged with increasing concentrations of CGRP, washed and challenged 
again with CGRP, 5 and 30 min later. This process was then repeated in the same 
arteries following incubation with SM-19712. The initial challenge with CGRP 
induced a concentration-dependent relaxation that was identical in the presence of 
vehicle and SM-19712 (CGRP pEC50, 10.16±0.05, vehicle; 10.13±0.04, SM-19712; 
n=4 for each group) (Figure 4A, Table 1). When challenged 5 min later, the potency 
of CGRP in both following both vehicle and SM-19712 treatment was reduced, 
indicating desensitization of CGRP receptors (CGRP pEC50, 9.67±0.06, vehicle; 
9.29±0.06, SM-19712; n=4 for each group) (Figure 4B, Table 1). When challenged 30 
min later, CGRP induced relaxation of vehicle-treated arteries with a similar potency 
to initial responses, indicating CGRP receptors had resensitized (CGRP pEC50, 
10.25±0.04; n=4) (Figure 4C, Table 1). In contrast, following treatment with SM-
19712, the pEC50 to the second challenge of CGRP was still reduced compared to A
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initial responses, indicating that CGRP receptors were still desensitized (CGRP 
pEC50, 9.65±0.09; n=4) (Figure 4C, Table 1). 
 
 
 
 
Discussion and Conclusions 
In this study, we demonstrate for the first time that ECE-1 regulates the 
resensitization of CGRP responses in SMCs and regulates CGRP-induced relaxation 
of mesenteric resistance arteries. CLR and RAMP1 are only coexpressed in the 
smooth muscle layer of mesenteric arteries, a finding that mimics the expression 
pattern observed in cranial arteries (Lennerz et al., 2008). Therefore, we used 
mesenteric resistance arteries not only as a suitable model to study CGRP receptor 
regulation in relation to migraine (without the technical difficulties associated with 
accessing cranial arteries), but also because of their importance in regulating blood 
pressure. Thus, given the important role of CGRP in pain transmission and regulation 
of vascular tone, our finding that ECE-1 regulates CGRP-induced responses in 
arteries may be an important development in the search for alternative strategies to 
treat migraine. 
We found that RMA-SMCs and mesenteric arteries contain mRNA for CLR, RAMP1 
and all four isoforms of ECE-1. Further, we observed ECE-1-immunoreactivity in the 
early endosomes of RMA-SMCs and in the smooth muscle layer of mesenteric 
arteries. Thus, ECE-1 is expressed in RMA-SMCs, which also express mRNA 
transcripts for CLR and RAMP1. Therefore, if CGRP internalizes to endosomes with 
CLR•RAMP1, as observed in transfected HEK cells (Cottrell et al., 2007; Padilla et A
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al., 2007), ECE-1 would be appropriately localized to degrade CGRP. In support of 
this finding, ECE-1-immunoreactivity has been detected in many types of human 
SMCs (Barnes et al., 1999; Granchi et al., 2002; Jackson et al., 2006). In human 
umbilical artery SMCs, ECE-1 was present in punctate perinuclear vesicles, similar to 
the early endosomal vesicles observed in our experiments (Barnes et al., 1999). ECE-
1 protein has also been detected in human temporal arteries (Lozano et al., 2010), 
although the location of ECE-1 in these vessels remains undetermined. Thus, we are 
the first to show the endosomal location of ECE-1 in SMCs, where it may degrade 
internalized CGRP and perhaps other neuropeptides, to regulate GPCR recycling and 
resensitization. 
Our experiments indicated that RMA-SMCs express a functional CGRP receptor. 
CGRP induced a concentration-dependent increase in levels of cAMP and 
phosphorylation of ERK1 and ERK2. In support of this observation, CGRP has been 
shown to induce accumulation of cAMP and/or phosphorylation of ERKs in many 
cell types, including smooth muscle, endothelial and epithelial cells (Hirata et al., 
1988; Kawase et al., 1999; Kubota et al., 1985; Van Valen et al., 1990; Yu et al., 
2006). One interpretation of our cAMP data is CGRP gives a typical biphasic curve, 
with the first increase (CGRP, 0.1-10 nM) reflecting activation of CLR•RAMP1. The 
latter increase (CGRP, 1 µM) probably reflecting the ability of CGRP to activate 
adrenomedullin receptors at high concentrations (Roh et al., 2004). However, further 
experimentation would be required to confirm the biphasic nature of the CGRP 
response in RMA-SMCs. This biphasic phenomenon of the CGRP response was not 
observed in our artery relaxation studies as 100% relaxation was achieved before 
using micromolar concentrations of CGRP.  A
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SM-19712 is a highly selective and potent inhibitor of ECE-1 that prevents the 
conversion of big endothelin-1 to endothelin-1 by solubilized rat lung microsomes 
(IC50, 42 nM) and by cultured porcine aortic endothelial cells (IC50, 31 µM). 
However, unlike other ECE-1 inhibitors such as phosphoramidon, which can inhibit 
metallopeptidases such as neprilysin (neutral endopeptidase 24.11) and angiotensin I-
converting enzyme (Kukkola et al., 1995) that may play a role in the metabolism of 
CGRP (Kramer et al., 2006; Tramontana et al., 1991), SM-19712 (10-100 µM) has no 
effect on these peptidases (Umekawa et al., 2000). Further selectivity was 
demonstrated by the lack of effect on agonist binding at numerous GPCRs, including 
the angiotensin II (type I and II) receptors, endothelin-1 (A and B) receptors, 
neuropeptide Y2 receptor and vasoactive intestinal peptide receptor (Umekawa et al., 
2000). ECE-1 regulates CGRP receptor resensitization in RMA-SMCs, as SM-19712 
inhibited the resensitization of CGRP-induced cAMP generation. This result was 
expected as ECE-1 regulates CGRP-induced Ca2+-signaling in cell lines. In HEK cells 
and a neuroblastoma cell line (SK-N-MC) that naturally expresses CLR and RAMP1 
(Van Valen et al., 1990), ECE-1 knockdown and the ECE-1 inhibitors, SM-19712 and 
PD069185 (Ahn et al., 1998) reduce resensitization of CGRP-induced Ca2+-signaling 
(McLatchie et al., 1998; Padilla et al., 2007). Conversely, ECE-1 overexpression 
promoted resensitization of CGRP-induced Ca2+-signaling (Padilla et al., 2007). 
Our results strongly suggest CGRP-induced relaxation is solely dependent on 
activation of CGRP receptors on SMCs, as inhibitors of nitric oxide generation (L-
NAME), prostaglandin production (indomethacin), and the endothelium-derived 
hyperpolarizing factor response (block of SKCa (apamin) and IKCa channels 
(TRAM34)) had no effect on CGRP-induced relaxation of these arteries. This finding 
is in agreement with a previous study showing that CGRP induces relaxation of rat A
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mesenteric arteries via a mechanism that depends minimally on the endothelium and 
K+-channel opening (Lei et al., 1994) and supported by the colocalization of CLR and 
RAMP1 only in the smooth muscle layer of mesenteric arteries (Cottrell et al., 2005). 
Interestingly, in rat dura mater and human cranial vessels CLR and RAMP1 have also 
been localized to the smooth muscle layers (Edvinsson et al., 2010; Oliver et al., 
2002), suggesting that CGRP may regulate brain blood flow via a similar mechanism 
to the one existing in the mesentery. Thus, the mesenteric artery may represent a 
useful model to study CGRP receptor regulation in relation to brain disorders.  
We further characterized the role of ECE-1 in regulation of CGRP responses by 
examining the effects of SM-19712 on CGRP-induced relaxation of isolated rat 
mesenteric arteries. ECE-1 inhibition had no effect on the pEC50 for initial challenges 
with CGRP, which is unsurprising, as ECE-1 does not affect [Ca2+]i mobilization to 
initial challenges of CGRP (Padilla et al., 2007). However, the potency of CGRP (5 
min later) was reduced in vehicle- and SM-19712-treated arteries, indicating CGRP 
receptor desensitization. Similarly, tachyphylaxis to CGRP has been observed in other 
studies using rat mesenteric arteries (Han et al., 1990) and rat intramural coronary 
arteries (Sheykhzade et al., 2004).  Although, the pEC50 following SM-19712-
treatment reflects a greater degree of desensitization, we hypothesize that this 
difference in potency is due to rapid recycling of CGRP receptors in the control group 
and not a greater desensitization/activation of CGRP receptors following SM-19712-
treatment. Indeed, at 30 min in arteries treated with vehicle, the pEC50 for CGRP-
induced relaxation had returned to initial values, indicating CGRP receptor 
resensitization. In contrast, ECE-1 inhibition prevented CGRP receptor resensitization 
at 30 min. The kinetics of resensitization we observed in arteries, were much faster 
than those observed in HEK-CLR RAMP1 cells (Padilla et al., 2007). However, A
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experimental conditions (CGRP concentration and time of exposure) were vastly 
different in the two experiments, which may account for this discrepancy. 
Furthermore, it may also reflect differences in levels of ECE-1 expression. Previous 
studies have shown that ECE-1 knockdown or overexpression can alter the kinetics of 
resensitization of ECE-1-regulated GPCRs (Padilla et al., 2007). If this ECE-1-
dependent mechanism operates in the cerebral sites implicated in migraine remains to 
be determined. However, as CLR and RAMP1 are expressed in the smooth muscle, 
but not endothelial layer of the cerebral vasculature (Oliver et al., 2002) it would 
seem likely, provided that ECE-1 is also expressed in this location. The degranulation 
of mast cells, which leads to the release of histamine, has also been suggested to play 
an important role in the pathophysiology of migraine (Levy, 2009; Sicuteri, 1963). It 
is well established that CGRP can trigger mast cell degranulation (Piotrowski et al., 
1986), but whether ECE-1 regulates the recycling and resensitization of CGRP 
receptors in mast cells has yet to be determined. However, if these cells do express 
ECE-1 it is likely that mast cell CGRP receptors would also be regulated by the same 
mechanism. 
It has been postulated that certain migraineurs may be sensitized to the effects of 
CGRP, by the upregulation of RAMP1 (Zhang et al., 2007). Indeed, mice 
overexpressing human RAMP1 demonstrate an increased sensitivity to CGRP and 
exhibit light-aversive behavior similar to photophobia in migraine patients (Recober 
et al., 2009). Another mechanism that may cause CGRP sensitization could be 
decreased CGRP receptor resensitization periods. Patients with increased ECE-1 
expression would have much reduced receptor recycling times (due to enhanced 
degradation of CGRP in endosomes) and thus be able to respond more quickly to 
subsequent releases of CGRP. Whether ECE-1 expression is altered in migraineurs is A
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not yet known, but it is an enticing possibility. In support of this notion, it has been 
reported that many migraineurs have elevated levels of endothelin-1 (a vasoactive 
peptide generated by the proteolytic activity of ECE-1) (Farkkila et al., 1992). This 
lead to the hypothesis that antagonism of endothelin A receptors would be an 
effective treatment for migraine. However, although bosentan, a selective endothelin 
A receptor antagonist was effective at reducing neurogenic plasma extravasation in 
rats, it was ineffective as a treatment in humans for migraine (May et al., 1996). 
The mechanism by which ECE-1 promotes recycling of GPCRs from endosomes back 
to the cell-surface to mediate resensitization of signalling appears to be common for 
receptors with peptide ligands that are substrates for ECE-1 only at endosomal pH and 
that exhibit a sustained interaction with β-arrestins (Padilla et al., 2007; Roosterman 
et al., 2007; Roosterman et al., 2008). In the acidified environment of endosomes, 
ECE-1 degrades the peptide ligands to inactive metabolites disrupting the peptide-
receptor-β-arrestin complex, allowing the receptor to recycle to the cell-surface. 
However, it remains to be determined whether this mechanism also controls CGRP-
induced endosomal-based signalling, as it does for substance P-induced ERK 
activation from the neurokinin-1 receptor (Cottrell et al., 2009).  
In conclusion, we report that vascular ECE-1 activity promotes the resensitization of 
CGRP-induced vasodilatation of mesenteric resistance arteries, by promoting 
resensitization of CLR•RAMP1. CGRP receptor blockade is a current strategy for the 
treatment of migraine. An advantage that ECE-1 inhibition would have over CGRP 
receptor antagonism would be the preservation of the acute effects of CGRP. For 
example, this would maintain the ability of CGRP to play a protective role during 
ischaemia caused by stroke, but would decrease responses to a more sustained release 
of CGRP, which may occur during a migraine attack. However, additional A
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experimentation is required, as inhibition of ECE-1 would reduce endothlin-1 
production, which in itself may cause vascular side effects. In conclusion, we believe 
inhibitors of endosomal ECE-1, by attenuating resensitization of CGRP receptors, 
may represent an alternative strategy for the treatment of migraine. 
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Figure Legends 
Figure 1. RMA-SMCs express CLR, RAMP1 and ECE-1 isoforms. (A) 
Expression of immunoreactive α-smooth muscle actin in cultures from rat mesenteric 
resistance arteries, indicating cultured cells are SMCs. Scale bar, 100 µm. (B) RT-
PCR amplification of mRNA for CLR (442 bp), ECE-1a (177 bp), ECE-1b (289 bp), 
ECE-1c (288 bp), ECE-1d (255 bp) and RAMP1 (277 bp) in RMA-SMCs. RT–
reverse transcriptase, bp–base pairs. (C) Immunoreactive ECE-1 was detected in 
vesicles in α-smooth muscle actin-positive cells. ECE-1 colocalizes with a marker for 
early endosomes (arrows), early endosomes antigen-1 (EEA1) in RMA-SMCs. Scale 
bar, 10 µm; n=3. 
Figure 2. ECE-1 regulates resensitization of CGRP-induced cAMP generation in 
RMA-SMCs. (A) Concentration response analysis of CGRP-induced cAMP 
generation in RMA-SMCs. CGRP induced a biphasic response indicating the 
presence of more than one receptor type in RMA-SMCs.  n=3 wells. (B) Western blot 
analysis of CGRP-induced phosphorylation of ERK in RMA-SMCs. CGRP induced a 
prompt increase in levels of phosphorylated ERK1 and ERK2 at 2 and 10 min. n=3 
(C) RMA-SMCs were incubated with vehicle (control) or SM-19712, stimulated with A
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vehicle (control) or CGRP (10 nM, 10 min), washed, incubated in CGRP-free 
medium (30 min) and cAMP accumulation to a second challenge of CGRP (10 nM) 
recorded.  SM-19712 reduced resensitization of CGRP-induced cAMP generation 
(vehicle, 70±12% and SM-19712, 35±10%). n=4, * p<0.05. 
Figure 3. Rat mesenteric arteries express ECE-1 and the CGRP receptor 
components, CLR and RAMP1. (A) RT-PCR amplification of mRNA for CLR (442 
bp), RAMP1 (277 bp), ECE-1a (177 bp), ECE-1b (289 bp), ECE-1c (288 bp), ECE-
1d (255 bp) in rat mesenteric arteries. RT–reverse transcriptase, bp–base pairs. (B) 
Localization of nuclei (DAPI), ECE-1 and PECAM-1 in whole mounts of rat 
mesenteric artery.  Immunoreactive ECE-1 was detected in the endothelial and SMC 
layers of mesenteric arteries (arrows). PECAM-1-immunoreactivity was only detected 
in the endothelial cell layer (arrows). Scale bar, 20 µm. (C) Immunoreactive CLR, 
RAMP1 and ECE-1 was detected in the smooth muscle layer of sections of 
mesenteric arteries (arrows). Nuclei are shown by DAPI staining. Scale bar, 50 µm; 
n=3. 
Figure 4. Effect of an ECE-1 inhibitor on CGRP-induced relaxation in rat 
mesenteric arteries. Arteries were incubated with vehicle (control), contracted with 
phenylephrine (0.3-10 µM), exposed to increasing concentrations of CGRP (1 pM-3 
nM), washed, contracted with phenylephrine and exposed again to increasing 
concentrations of CGRP (1 pM-3 nM). Arteries were then incubated with SM-19712 
(ECE-1 inhibitor, 10 µM) and experimentation repeated. (A) Incubation of arteries 
with SM-19712 had no effect on initial responses to CGRP. (B, C) SM-19712 shifted 
the pEC50 to a second challenge of CGRP at both 5 and 30 min after the initial 
challenge. n=4 arteries for each group. A
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 Vehicle SM-19712 
Initial Response 10.16±0.05 10.13±0.04 
5 min Recovery 9.67±0.06* 9.29±0.06* 
30 min Recovery 10.25±0.04 9.65±0.09* 
Table 1. Effect of ECE-1 inhibition on CGRP-induced relaxation in rat 
mesenteric arteries. Arteries were incubated with vehicle (control), contracted with 
phenylephrine (0.3-10 µM), exposed to increasing concentrations of CGRP (1 pM-3 
nM), washed, contracted with phenylephrine and exposed again to increasing 
concentrations of CGRP (1 pM-3 nM). Arteries were then incubated with SM-19712 
(ECE-1 inhibitor, 10 µM) and experimentation repeated. pEC50 values for initial 
responses and subsequent challenges, 5 and 30 min after initial challenge in the 
presence of vehicle (control) or SM-19712. n=4 arteries for each group. * p≤0.005 
compared to vehicle- and SM-19712-treated arteries (initial response).  
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